Of Transformation Technology Summary Starting October 13 with low code / no code: Enable enterprise efficiency. Sign up now!
Dr. Joe Alexander, Director of NTT Research Medical & Health Informatics Lab Laboratory, outlined VentureBeat’s future vision for bio-digital twins.
Japan’s telecom giant NTT has launched a major initiative to improve digital health through the use of digital twin technology. This project is part of NTT’s new R&D Center, which focuses on basic research. The goal is to solve long-term technological problems with successful businesses and solutions that can have a positive impact on many areas of our lives. These projects are not tied to specific product release plans, but can bring far-reaching improvements far beyond conventional increased research.
The reason behind the digital twin application
VentureBeat – What exactly are medical and health information providers – where does it fit in with the features of other corporate medical software such as IHRS, diagnostics, telemedicine and research?
Dr. Joe Alexander – Medical Informant is a sub-discipline of health information that directly affects the patient-physician relationship. It focuses on information technology that enables effective data collection through the use of technology tools to develop medical knowledge and facilitate patient care delivery. The purpose of medical informants is to ensure access to critical patient information when and where it is necessary to make medical decisions. Medical Informants also focus on the management of medical information for research and education.
Access, storage, retrieval, and use of health care information is a study of health care providers to improve collaboration between different health care providers. It plays a vital role in pushing for better health care. Health Informants are a growing industry that combines information technology, communications and health care to improve the quality and safety of patient care. EHRs help providers better manage patient care and are an important part of health information providers.
The purpose of telemedicine to treat patients remotely has to do with access to and sharing of medical information. The term “tests” can be applied to any procedure or device that involves techniques for (medical) tests.
One area of current research that is of particular interest to our team is proper cardiology. This includes cardiovascular bio-digital twins as well as heart-on-chip technologies.
Research on MEI labs does not currently involve EHR software development or telemedicine in isolation. Our work supports remote monitoring, diagnostics and advanced treatments.
VentureBeat: What is the initiative of Bio Digital Twin, and how do you plan to promote it?
Alexander Bio Digital Twin is an electronic virtual representation that provides up-to-date insights into real-world real estate situations to enable better management and inform decision-making. This concept has been applied to the maintenance of jet engines and can also be applied to health forecast maintenance.
The BioDIT Initiative aims to adapt and transform health care on an individual basis using biodegradable technologies. By developing cardiovascular biodegradation (CV) and cardiac-chip platforms, we will first be able to achieve accurate cardiac care on many scales. CV bioditi is at the level of the entire body physiology system, heart-on-chip at the level of microfluidics, and uses the individual stem cells in vitro organs.
For CV BioDT, we start with emergencies (acute myocardial infarction and acute heart failure) and chronic cardiovascular conditions and their common diseases and complications. The latter requires a serious dependence on the cardiovascular system. Finally, based on our knowledge of basic physiological and pathogenic mechanisms (along with advanced sensory technologies), we move on to safety and prevention.
Can digital twins save lives in healthcare?
VentureBeat – What is the value of a digital twin, and how is it built on other technologies to capture and manage medical information or simulate things?
Alexander We hope that our bio-digital twins will better enhance personal care. Based on causal mechanisms, we need to be able to duplicate the individual’s general physiology, predict health issues, and provide recommendations for the treatment of complex patients with a “what-is” diagnosis.
Automated treatments – provided by bio-digital twins – may be possible, with the doctor simply monitoring the equipment. Virtual clinical trials in bio-twin populations are also possible and significantly accelerate drug development (or vaccination).
What we present is not evolution, but revolutionary. A large project of this scope and scale takes time. For facilitative impact points, we are constantly constantly looking for ways to develop clinical and technological landscapes.
VentureBeat: Why did you decide to start with the heart, and how does this meet other similar efforts?
Alexander Globally, we are suffering from cardiovascular disease. One of the main missions of New Testament research is to provide long-term benefits to mankind; This is fundamental to deciding which projects to follow.
Our immediate cardiovascular disease targets are acute heart failure (AMI) and acute heart failure (acute HF). We will follow up with chronic heart attack and other conditions later.
VentureBeat: What’s next in digital twins and why?
Alexander Following the development of CV biodegradation, our next search will be for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The reason here is the same – neurodegenerative diseases are at least the 2nd leading cause of death in the United States
The components on the chip
VentureBeat: What are you doing with nano- and micro-sensors and electrodes?
Alexander MEI Lab is developing organ-on-chip microfluidide platforms as well as three-dimensional convertible and implanted electrodes. This work involves the testing and testing of new materials, including nanoparticles and nanofiber-based paper electrodes.
VentureBeat: Which ones are the most promising in the short term and in the long term?
Alexander This is a difficult question for me to answer because I have not been directly involved in research. However, all of our goals are long-term. Based on current developments, microscopic three-dimensional alternating electrodes are more promising in the short term, followed by similar types of electrodes to stimulate and stimulate. Body-on-chip platforms can be mature in the long run.
VentureBeat: What are some key advances in digital biomarkers, wearable technologies, and remote navigation?
Alexander While we are in the process of conducting clinical and technical landscaping of such devices, we have not yet developed a strategy in the MEI laboratory to point us in any particular direction. We are currently focusing on emergencies where patients are admitted to the hospital and where they can receive direct visual information necessary for pre-model construction, verification and verification.
VentureBeat’s mission is to be a digital city square for technical decision makers to learn about alternative technology and marketing. Our site provides important information on information technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community:
- Up-to-date information on topics you are looking for
- Our newspapers
- Discounted access to content intended by the Lord and our prestigious events such as ours 2021 transition: know more
- Network features and more